ReviewJournal of clinical microbiology2022
What's New in Antibiograms? Updating CLSI M39 Guidance with Current Trends.
Review in Journal of clinical microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 61 citations in OpenAlex.
- Patterns of Antibiotic Utilization and Bacterial Susceptibility of Prenatal Urinary Tract Infections.Journal of women's health (2002) · 2026Article
- Beyond the Cumulative Antibiogram: A Weighted-Incidence Syndromic Combination Antibiogram to Guide Empirical Therapy of Bloodstream Infections in the Emergency Department.Infectious diseases and therapy · 2026Article
- Persistent Non-Journal of fungi (Basel, Switzerland) · 2026Article
- Beyond the Standard Antibiogram: Unveiling the Roles of pH and Salinity in Modulating Gentamicin Efficacy Against Escherichia coli in Urinary Tract Infections.MicrobiologyOpen · 2026Article
- Stratified cumulative antibiograms and antimicrobial resistance trends among hospitalized patients in a Chinese tertiary hospital: a 7-year retrospective study.World journal of microbiology & biotechnology · 2026Article
- Three-year cumulative antibiogram of breast-associated secretion and drainage specimens in female patients in Syria (2022-2024): microbiologic spectrum, antimicrobial susceptibility, and annual MSSA trends.BMC microbiology · 2026Article
- Leveraging patient data to detect systematic shifts in daptomycin susceptibility testing associated with reduced prescribing.Journal of clinical microbiology · 2026Article
- Prevalence, trend and resistance patterns of carbapenem-resistant Enterobacterales in Bangladesh: a nationwide laboratory-based study.BMC infectious diseases · 2026Article
- Epidemiology, Clinical Microbiology and Antimicrobial Therapy: A Shared Effort Against Infectious Diseases.Antibiotics (Basel, Switzerland) · 2026Article
- OrgTRx: A Platform Developed in Queensland for the Extraction and Visualisation of Antimicrobial Susceptibility Data for the Surveillance of Resistance in Microorganisms.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Interpreting antimicrobial resistance from bacterial whole-genome sequencing: prediction tools, database fragmentation, analytical trade-offs, and harmonized reporting.Frontiers in microbiology · 2026Review
- Antimicrobial Resistance Profiles of Bacterial Isolates from Purulent Specimens in Women and Children: A Six-Year Retrospective Study in Central China.Infection and drug resistance · 2026Article
- Catheter-associated urinary tract infection and associated factors among patients admitted to intensive care unit at King Abdullah Hospital, Bisha, Saudi Arabia.BMC infectious diseases · 2025Article
- Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.The Journal of antimicrobial chemotherapy · 2025Article
- Impact of an antimicrobial stewardship program on optimizing linezolid consumption and susceptibility in intensive care unit patients with methicillin-resistance staphylococcus aureus: a retrospective cohort study.BMC infectious diseases · 2025Article
- Time Trends in Prevalence and Antimicrobial Resistance of Respiratory Pathogens in a Tertiary Hospital in Rome, Italy: A Retrospective Analysis (2018-2023).Antibiotics (Basel, Switzerland) · 2025Article
- Evaluating a Targeted Antimicrobial Stewardship Program and Its Temporal Association with Resistance Trends in a Veterinary Referral Hospital.Veterinary sciences · 2025Article
- Investigation of Bacterial Species and Their Antimicrobial Drug Resistance Profile in Feline Urinary Tract Infection in Thailand.Animals : an open access journal from MDPI · 2025Article
- Exploring variability in antibiograms: a cross-sectional study.JAC-antimicrobial resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A vast amount of antimicrobial susceptibility test (AST) data is generated from routine testing in diagnostic laboratories for the primary purpose of guiding clinicians in antimicrobial therapy decisions for their patients. However, there is additional value for these data when they are compiled at the local, regional, national, and global levels. Cumulative AST data can be used to prepare antibiograms at the individual health care facility level. These reports can be used to gain insight into appropriate empirical therapy options prior to the availability of AST results on an individual patient's isolate. Different types of cumulative AST data reports can also be compiled at the regional, national, and global levels to estimate susceptibility rates in geographic regions, document trends in evolving microbial populations, and recognize the appearance and spread of emerging antimicrobial resistance threats. The first CLSI M39 Guideline for Analysis and Presentation of Cumulative AST Data was published in 2000. Since that time, there have been changes to AST and reporting recommendations as well as the introduction of advanced informatics technologies to analyze and present data. The 5th edition of M39 has taken into consideration these changes to assist those who analyze, present, and utilize routine antibiograms and other types of cumulative AST data reports as well as those who design information systems for the capturing and analyzing of AST data. Furthermore, antimicrobial stewardship programs (ASPs) have expanded considerably, and uses of the antibiogram by ASPs have been addressed. This minireview will remind users of the basic recommendations for analysis and presentation of antibiograms and provide new suggestions to enhance these reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.